Global economic burden of schizophrenia: response to authors’ reply

Global economic burden of schizophrenia: response to authors’ reply

Amanda L Neil,1 Vaughan J Carr2,3 1Menzies Institute for Medical Research, The University of Tasmania, Hobart, TAS, 2Research Unit for Schizophrenia Epidemiology, University of New South Wales, Sydney, NSW, 3Department of Psychiatry, School of Clinical Sciences, Monash University, Melbourne, VIC, A...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Neil AL, Carr VJ
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Cost of illness
systematic review
schizophrenia
psychosis
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/30385dccc0bf4dfa8a3f1cabf4953b02
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:30385dccc0bf4dfa8a3f1cabf4953b02
record_format dspace
spelling oai:doaj.org-article:30385dccc0bf4dfa8a3f1cabf4953b022021-12-02T02:43:33ZGlobal economic burden of schizophrenia: response to authors’ reply1178-2021https://doaj.org/article/30385dccc0bf4dfa8a3f1cabf4953b022017-02-01T00:00:00Zhttps://www.dovepress.com/global-economic-burden-of-schizophrenia-response-to-authorsrs-reply-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Amanda L Neil,1 Vaughan J Carr2,3 1Menzies Institute for Medical Research, The University of Tasmania, Hobart, TAS, 2Research Unit for Schizophrenia Epidemiology, University of New South Wales, Sydney, NSW, 3Department of Psychiatry, School of Clinical Sciences, Monash University, Melbourne, VIC, AustraliaFor clarification, we undertook bottom-up costing using individual participant data from the Low Prevalence Disorders Study in our costing study.1 We did not use the data reported in the study by Carr et al2 as asserted by Chong et al.3 Chong et al have thus misunderstood and thus misrepresented our methodology in both their systematic review4 and their response to our letter.5 Authors' reply  Huey Yi Chong,1 Nathorn Chaiyakunapruk1–41School of Pharmacy, Monash University Malaysia, Selangor, Malaysia; 2Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; 3School of Pharmacy, University of Wisconsin, Madison, USA; 4School of Population Health, University of Queensland, Brisbane, Australia We thank Dr Neil and Professor Carr for their clarification on the data source used in their study.1 In this regard, we would like to highlight one of the most common challenges when conducting any systematic review, for example economic burden of schizophrenia in this case – the marked diversity in reporting among the included studies, which increases the likelihood of any potential misinterpretation. In convergence with a number of published systematic reviews of economic burden studies,2–5 there has been a consistent call for a more explicit reporting in various aspects of an economic burden study, thus readability and transparency can be enhanced. However, a standardized guide/checklist for conducting and reporting economic burden is yet to be available. On the final note, we strongly urge for the development of such a guidance document to improve the quality and clarity of an economic burden study. View original paper by Chong et al View original Letter by Neil and Carr  Neil ALCarr VJDove Medical PressarticleCost of illnesssystematic reviewschizophreniapsychosisNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 457-458 (2017)
institution DOAJ
collection DOAJ
language EN
topic Cost of illness
systematic review
schizophrenia
psychosis
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
spellingShingle Cost of illness
systematic review
schizophrenia
psychosis
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Neil AL
Carr VJ
Global economic burden of schizophrenia: response to authors’ reply
description Amanda L Neil,1 Vaughan J Carr2,3 1Menzies Institute for Medical Research, The University of Tasmania, Hobart, TAS, 2Research Unit for Schizophrenia Epidemiology, University of New South Wales, Sydney, NSW, 3Department of Psychiatry, School of Clinical Sciences, Monash University, Melbourne, VIC, AustraliaFor clarification, we undertook bottom-up costing using individual participant data from the Low Prevalence Disorders Study in our costing study.1 We did not use the data reported in the study by Carr et al2 as asserted by Chong et al.3 Chong et al have thus misunderstood and thus misrepresented our methodology in both their systematic review4 and their response to our letter.5 Authors' reply  Huey Yi Chong,1 Nathorn Chaiyakunapruk1–41School of Pharmacy, Monash University Malaysia, Selangor, Malaysia; 2Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand; 3School of Pharmacy, University of Wisconsin, Madison, USA; 4School of Population Health, University of Queensland, Brisbane, Australia We thank Dr Neil and Professor Carr for their clarification on the data source used in their study.1 In this regard, we would like to highlight one of the most common challenges when conducting any systematic review, for example economic burden of schizophrenia in this case – the marked diversity in reporting among the included studies, which increases the likelihood of any potential misinterpretation. In convergence with a number of published systematic reviews of economic burden studies,2–5 there has been a consistent call for a more explicit reporting in various aspects of an economic burden study, thus readability and transparency can be enhanced. However, a standardized guide/checklist for conducting and reporting economic burden is yet to be available. On the final note, we strongly urge for the development of such a guidance document to improve the quality and clarity of an economic burden study. View original paper by Chong et al View original Letter by Neil and Carr  
format article
author Neil AL
Carr VJ
author_facet Neil AL
Carr VJ
author_sort Neil AL
title Global economic burden of schizophrenia: response to authors’ reply
title_short Global economic burden of schizophrenia: response to authors’ reply
title_full Global economic burden of schizophrenia: response to authors’ reply
title_fullStr Global economic burden of schizophrenia: response to authors’ reply
title_full_unstemmed Global economic burden of schizophrenia: response to authors’ reply
title_sort global economic burden of schizophrenia: response to authors’ reply
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/30385dccc0bf4dfa8a3f1cabf4953b02
work_keys_str_mv AT neilal globaleconomicburdenofschizophreniaresponsetoauthorsrsquoreply
AT carrvj globaleconomicburdenofschizophreniaresponsetoauthorsrsquoreply
_version_ 1718402209170849792

Ejemplares similares